Home › Embrace Low-Cap Biotech For High Gains: Eden Rahim Of Next Edge Capital
 

Keywords :   


Embrace Low-Cap Biotech For High Gains: Eden Rahim Of Next Edge Capital

2016-03-03 17:14:01| Biotech - Topix.net

Biotech is a slow-growth world, but if you can show good organic growth, the market will eventually pay up. Eden Rahim of Toronto-based Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks.

Tags: high capital edge gains

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.04Markets rocked as US says Israel has struck Iran
19.04Netflix profits soar after password crackdown
19.04US interest rate setter says 'no hurry' to cut
19.04Egal Pads Honored at Women\'s Health Summit
19.04Can TikTok's owner afford to lose its killer app?
19.04Almost a quarter of kids aged 5-7 have smartphones
19.04Why a deluge of Chinese-made drugs is hard to curb
19.04Meet the 2024 Waste360 Women Who Inspire
More »